A patient might start overweight with chronic fatigue, brain fog, and severe trouble losing weight on an aggressive Tier 3 metabolic restoration stack
Tirzepatide, a novel dual GLP-1 and GIP analogue, was investigated at weekly subcutaneous doses of 5mg, 10mg and 15 mg compared to 1 mg semaglutide for 40 weeks in patients living with T2DM in the SURPASS phase 3 clinical trial program
Keywords: Retatrutide, Triple agonist, Glucagon, Obesity, Type 2 diabetes, GLP-1 Introduction Obesity is a chronic progressive disease that increases the risk of multiple obesity-related complications such as cancer and cardiovascular disease and is associated with impaired quality of life, and reduced life expectancy [1]
Gao, F., Wu, D
What FDA-approved treatments or non-drug options are available, and why might they be preferred